Finland· FI-REL-REL61394
HETRONIFLY
A serplulimab product containing serplulimab, registered in Finland by Accord Healthcare S.L.U.. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Serplulimab is registered in 11 of 19 countries.
Countries holding a registration under ATC L01FF12 (serplulimab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Serplulimab · ATC L01FF12
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Fimea (Finland)- Active substance
- Serplulimab
- Manufacturer
- Accord Healthcare S.L.U.
- Country
- Finland (FI)
- ATC code
- L01FF12
- ATC class
- Serplulimab
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Serplulimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumHetronifly 10 mg/mlAccord Healthcare
- SwitzerlandHetronifly 100 mg/10 ml, Konzentrat zur Herstellung einer InfusionslösungAccord Healthcare AG
- CzechiaHETRONIFLYAccord Healthcare S.L.U., Barcelona
- IrelandHETRONIFLY 10 mg/ml concentrate for solution for infusionAccord Healthcare S.L.U.
- IcelandHETRONIFLYAccord Healthcare S.L.U.
- NorwayHetroniflyAccord Healthcare S.L.U.
- PolandHetroniflyAccord Healthcare S.L.U.
- SwedenHETRONIFLY 10 mg/ml Koncentrat till infusionsvätska, lösningAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Hetronifly
- Iceland · Hetronifly
- Liechtenstein · Hetronifly
- Norway · Hetronifly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2845255-dede-4bc2-ac12-6648a9d2d438 GET /v1/drugs/b2845255-dede-4bc2-ac12-6648a9d2d438?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "10 mg/ml",
"atc_label": "serplulimabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/24/1870/001",
"fimea_rel_id": "REL61394",
"authorised_at": "2025-02-03"
}See everything about serplulimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.